Our Regular Weekly “Surfers”
HEP Dynamics LLC, Go To Market Advisors, LLC
Owner and Principle of HEP Dynamics, sponsor Surfing the NASH Tsunami, a weekly podcast in which a panel of experts discusses commercial developments and challenges in the global NASH market.
Founder and Medical Director, Tawazun Health
Louise has over 35-years experience working in the Healthcare Industry in UK and elsewhere in the world, including Europe, Middle East and Australia.
Dr. Alina M. Allen is a gastroenterologist in Rochester, Minnesota and is affiliated with Mayo Clinic. She received her medical degree from University of Medicine and Pharmacy ‘Gr T Popa” Iasi and has been in practice between 11-20 years
Amy Articolo, DO, FACOG, FACOOG, Dipl of ABOM, graduated from the University of Pennsylvania, the Philadelphia College of Osteopathic Medicine, and the University of Medicine and Dentistry of NJ, and is board-certified in Obstetrics and Gynecology and Obesity Medicine.
Global Liver Institute
Andrew Scott leads Global live Institute’s (GLI) policy department by actively advancing patient-centric strategies through undertaking proactive legislative and regulatory initiatives that positively improve the lives of all impacted by liver disease.
Anthony’s experience with liver disease motivated him to form NASH kNOWledge, a non-profit corporation with the mission of increasing public awareness of nonalcoholic liver disease.
President and CEO, Global Liver Institute
Donna R. Cryer, JD is Founder, President and Chief Executive Officer of the Global Liver Institute (GLI), the only patient-driven liver health nonprofit operating in the US and Europe.
University of Leeds and Leeds Teaching Hospitals NHS Trust
Ian is a Senior Lecturer at the University of Leeds and Honorary Consultant Hepatologist at the Liver Unit at St James’s University Hospital in Leeds.
Liver Institute Northwest, Clinical Professor, Elson S. Floyd College of Medicine at Washington State University
Dr. Kris Kowdley, Director of Liver Institute Northwest and clinical professor, Elson S. Floyd College of Medicine at Washington State University, is an internationally recognized liver disease expert and researcher.
Michelle T. Long, MD, MSc is a physician-scientist with an expertise in Nonalcoholic fatty liver disease (NAFLD), and an Associate Professor of Medicine at Boston University.
Erin Quirk, M.D. is President, Chief Medical Officer, and Head of Research & Development at Terns Pharmaceuticals, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH).
CEO of Sonic Incytes
A serial entrepreneur in healthtech, co-founding Sonic Incytes, developers of Velacur, the world’s first handheld 3D liver tissue assessment tool with diagnostic accuracy comparable to MRI elastography.
Hagan currently serves as Chief Commercial Officer at ModifyHealth. With over 15 years in the GI/Endoscopy space, Hagan has a history of commercializing innovative products and services that have dramatic impact on patient care. Prior to ModifyHealth, Hagan served as Senior Director of Marketing at EndoChoice and Marketing Channel Manager for the GI ASC Division at Boston Scientific.
National Research Institute
Dr. Juan Pablo Frias is Medical Director and Principal Investigator of National Research Institute in Los Angeles, CA. He has been involved in diabetes and metabolism-related research for over 25 years and has authored numerous publications in this field.
The University of Florida at Gainesville
Dr. Cusi is a Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville (2011-present). He is also a faculty and researcher at the Endocrinology, Diabetes and Metabolism Division at the Veterans Administration Medical Center at Gainesville, FL.
Antaros Medical AB
Lars Johansson is PhD in translational imaging from Uppsala University in Sweden. He has over 170 published peer-reviewed papers and several book chapters in imaging in drug development. He has over 30 years experience from clinical imaging in the cardiorenal and metabolic disease areas and more than 20 years experience from the pharma industry.
MPH, FACP, FACG, FAASLD Professor of Medicine Duke University
Manal F. Abdelmalek, MD, MPH is a tenured Professor of Medicine in the Division of Gastroenterology and Hepatology and Director of the Nonalcoholic Fatty Liver Disease (NAFLD) Clinical Research Program at Duke University.
Northwestern University Feinberg School of Medicine
Dr. Rinella is a Professor of Medicine at Northwestern University Feinberg School of Medicine and is the Director of the Northwestern Fatty Liver Program.
Chief Innovation Officer, Perspectum, Ltd.
Matt Kelly is Perspectum’s Chief Innovation Officer, overseeing clinical studies and collaborations to support our technology and explore novel indications.
U Chicago Medicine
Michael Charlton, MBBS, is an internationally renowned specialist in liver diseases and transplant medicine. Listed among “America’s Top Doctors” and “Best Doctors in America,” Dr. Charlton has particular expertise in the diagnosis, treatment and management of nonalcoholic fatty liver disease (nonalcoholic steatohepatitis) and viral hepatitis.
Section Chief of Hepatology at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical Center.
Michael Curry is the Section Chief of Hepatology at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical Center.
Director of the Fatty Liver Program, Arizona Liver Health
Naim Alkhouri, M.D., is the VP of Academic Affairs, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health (ALH) in Phoenix, AZ.
Jörn M. Schattenberg, M.D. received his medical degree from the University of Mainz, Germany in 2002 after studying Medicine in Mainz (Germany) and at the Tulane University in New Orleans (US) .
Rachel Zayas, is the Founder and CEO of AGED Diagnostics, has a Masters in Genetics and an MBA, has previously launched a biotech venture and worked at MIT in cancer research developing gene silencing therapeutics through RNA interference.
Indiana University School of Medicine
Dr. Samer Gawrieh is an Associate Professor of Clinical Medicine and the Director of the Hepatology Research Fellowship Program in the Division of Gastroenterology and Hepatology at Indiana University School of Medicine.
In 2017, Terri was diagnosed with NASH Cirrhosis. In 2018, she was diagnosed with HCC and has had 4 localized regional treatments. She is currently on the transplant list waiting for a second chance at a life-giving liver.